文献速递胃肠动力与功能性疾病

随机临床试验:利那洛肽与安慰剂对比——脑肠双向轴研究

Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
PubMed 文献 · Aliment Pharmacol Ther · 2020-05-13

利那洛肽较基线延长直肠皮层诱发电位潜伏期并提高最大耐受直肠容积,腹痛、排便频率及生活质量较安慰剂改善,但传入与传出信号较安慰剂无差异。

要点

  • 利那洛肽较基线延长直肠皮层诱发电位潜伏期,但组间无差异。
  • 利那洛肽较安慰剂显著提高最大耐受直肠容积并改善腹痛与IBS-QOL。
  • 利那洛肽与安慰剂总体应答率无显著差异(54% vs 23%,P=0.13)。

核心结论

  • 利那洛肽较基线延长传入性脑肠信号传导,但传入与传出信号较安慰剂均无影响。
  • 利那洛肽较安慰剂显著改善直肠高敏感、IBS-C症状及生活质量,可能解释其镇痛机制。

研究设计与样本

  • 随机临床试验,IBS-C(罗马III)伴直肠高敏感患者按2:1随机接受利那洛肽290µg或安慰剂治疗10周。
  • 采用肛门直肠电刺激及经颅/经脊髓-肛门直肠磁刺激评估脑肠双向轴,球囊扩张检查直肠感觉。
  • 主要结局为直肠-皮层及皮层-直肠诱发电位潜伏期。

主要发现

  • 直肠皮层诱发电位潜伏期(毫秒)利那洛肽较基线显著延长(P1:Δ 19 ± 6,P < 0.005;N1:Δ 20 ± 7,P < 0.02),安慰剂无显著变化(P1:Δ 3 ± 5;N1:Δ 4.7 ± 5,P = 0.3),组间无差异。
  • 传出性皮层-肛门直肠及脊髓-肛门直肠潜伏期无变化。
  • 最大耐受直肠容积(cc)利那洛肽较基线(P < 0.001)及安慰剂(Δ 29 ± 10 vs 4 ± 20,P < 0.03)显著增加。
  • 利那洛肽较基线腹痛减轻(P < 0.001),但组间无差异;完全自发排便频率增加(P < 0.001),IBS-QOL评分较基线及安慰剂改善(P = 0.01)。
  • 利那洛肽与安慰剂总体应答率无差异(54% vs 23%,P = 0.13)。

临床怎么用

  • 利那洛肽290µg治疗10周可改善IBS-C患者直肠高敏感、腹痛、排便频率及生活质量。
  • 其镇痛作用可能部分通过调节传入性脑肠信号传导实现。

局限性

  • 传入与传出信号传导较安慰剂未见显著差异,机制解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Linaclotide, a guanylate cyclase C agonist relieves irritable bowel syndrome with predominant constipation (IBS-C) symptoms, but how it improves pain in humans is unknown. AIMS: To investigate the effects of linaclotide and placebo on the afferent and efferent gut-brain-gut signalling in IBS-C patients, in a randomised clinical trial. METHODS: Patients with IBS-C (Rome III) and rectal hypersensitivity were randomised (2:1) to receive linaclotide (290 µg) or placebo for 10 weeks and undergo bi-directional gut and brain axis assessment using anorectal electrical stimulations and transcranial/transspinal-anorectal magnetic stimulations. Rectal sensations were examined by balloon distention. Assessments included abdominal pain, bowel symptoms and quality of life (QOL) scores. Primary outcomes were latencies of recto-cortical and cortico-rectal evoked potentials. RESULTS: Thirty-nine patients participated; 26 received linaclotide and 13 received placebo. Rectal cortical evoked potentials latencies (milliseconds) were significantly prolonged with linaclotide compared to baseline (P1:Δ 19 ± 6, P < 0.005; N1:Δ 20 ± 7, P < 0.02) but not with placebo (P1:Δ 3 ± 5; N1:Δ 4.7 ± 5,P = 0.3) or between groups. The efferent cortico-anorectal and spino-anorectal latencies were unchanged. The maximum tolerable rectal volume (cc) increased significantly with linaclotide compared to baseline (P < 0.001) and placebo (Δ 29 ± 10 vs 4 ± 20, (P < 0.03). Abdominal pain decreased (P < 0.001) with linaclotide but not between groups. Complete spontaneous bowel movement frequency increased (P < 0.001), and IBS-QOL scores improved (P = 0.01) with linaclotide compared to baseline and placebo. There was no difference in overall responders between linaclotide and placebo (54% vs 23%, P = 0.13). CONCLUSIONS: Linaclotide prolongs afferent gut-brain signalling from baseline but both afferent and efferent signalling were unaffected compared to placebo. Linaclotide significantly improves rectal hypersensitivity, IBS-C symptoms and QOL compared to placebo. These mechanisms may explain the effects of linaclotide on pain relief in IBS-C patients. ClinicalTrials.Gov: Registered at Clinical trials.gov no NCT02078323.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Rao SSC, Xiang X, Yan Y, et al. Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis. Aliment Pharmacol Ther. 2020. PMID: 32406112. doi:10.1111/apt.15772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。